Multiple Sclerosis Therapeutics Market Key Players Analysis by 2031 The Multiple Sclerosis (MS) Therapeutics Market focuses on the development and distribution of treatments for multiple sclerosis, a chronic autoimmune disease that affects the central nervous system. With a growing patient population and advances in research, this market is witnessing significant growth and innovation. The Multiple Sclerosis Therapeutics Market size was estimated to be US$ 29.84 billion in 2023 and is expected to reach US$ 53.77 billion by 2031; it is estimated to record a CAGR of 6.8% till 2031. Top Key Players • Merck and CO Inc • Novartis AG • Bayer AG • Sanofi • Bristoll-Myers Squibb • Horizon Therapeutics • Teva Pharmaceuticals • Takeda Pharmaceuticals • F.Hoffmann-La Roche • Biogen The Multiple Sclerosis Therapeutics Market is expanding rapidly, driven by advancements in treatment options and a rising awareness of the disease. As research progresses and new therapies emerge, patients with MS are likely to benefit from improved management strategies and enhanced quality of life. This market represents a critical area of focus for healthcare professionals and researchers aiming to make significant strides in the fight against multiple sclerosis. https://www.theinsightpartners.com/assets/rd-new-images/players_concentration/multiple-sclerosis-market-speedometer.webp